JCIC Asset Management Inc. Purchases 665 Shares of Novo Nordisk A/S (NYSE:NVO)

JCIC Asset Management Inc. boosted its position in Novo Nordisk A/S (NYSE:NVO) by 1.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 37,207 shares of the company’s stock after purchasing an additional 665 shares during the period. Novo Nordisk A/S comprises 1.3% of JCIC Asset Management Inc.’s holdings, making the stock its 26th largest position. JCIC Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $3,201,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of NVO. Cooper Financial Group boosted its stake in shares of Novo Nordisk A/S by 5.7% during the 4th quarter. Cooper Financial Group now owns 11,072 shares of the company’s stock worth $952,000 after acquiring an additional 593 shares during the period. Wedmont Private Capital boosted its position in Novo Nordisk A/S by 3.0% during the fourth quarter. Wedmont Private Capital now owns 11,450 shares of the company’s stock worth $988,000 after purchasing an additional 330 shares during the period. Talbot Financial LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at $4,066,000. Westmount Partners LLC lifted its stake in shares of Novo Nordisk A/S by 13.1% during the 4th quarter. Westmount Partners LLC now owns 2,405 shares of the company’s stock worth $207,000 after buying an additional 279 shares during the last quarter. Finally, Salem Investment Counselors Inc. boosted its holdings in shares of Novo Nordisk A/S by 2.3% during the 4th quarter. Salem Investment Counselors Inc. now owns 21,926 shares of the company’s stock worth $1,886,000 after buying an additional 491 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on NVO shares. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Finally, BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Price Performance

NVO stock traded down $1.93 during mid-day trading on Monday, hitting $84.33. The stock had a trading volume of 5,607,502 shares, compared to its average volume of 7,144,377. The firm has a fifty day simple moving average of $100.35 and a 200 day simple moving average of $119.04. Novo Nordisk A/S has a 52 week low of $81.50 and a 52 week high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $378.43 billion, a P/E ratio of 27.29, a P/E/G ratio of 1.37 and a beta of 0.45.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.